183 related articles for article (PubMed ID: 27368006)
1. Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion.
Verma A; Phua CK; Sim WY; Algoso RE; Tee KS; Lew SJ; Lim AY; Goh SK; Tai DY; Kor AC; Ho B; Abisheganaden J
Medicine (Baltimore); 2016 Jun; 95(26):e3996. PubMed ID: 27368006
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions.
Kasapoglu US; Arınç S; Gungor S; Irmak I; Guney P; Aksoy F; Bandak D; Hazar A
Clin Respir J; 2016 Nov; 10(6):791-799. PubMed ID: 25764010
[TBL] [Abstract][Full Text] [Related]
3. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma.
Verma A; Chopra A; Lee YW; Bharwani LD; Asmat AB; Aneez DB; Akbar FA; Lim AY; Chotirmall SH; Abisheganaden J
Curr Drug Discov Technol; 2016; 13(2):68-76. PubMed ID: 27216707
[TBL] [Abstract][Full Text] [Related]
4. Survival of lung adenocarcinoma patients with malignant pleural effusion.
Wu SG; Yu CJ; Tsai MF; Liao WY; Yang CH; Jan IS; Yang PC; Shih JY
Eur Respir J; 2013 Jun; 41(6):1409-18. PubMed ID: 23018906
[TBL] [Abstract][Full Text] [Related]
5. Prognosis of
Kashiwabara K; Fuji S; Tsumura S; Sakamoto K
Anticancer Res; 2020 Feb; 40(2):1117-1121. PubMed ID: 32014962
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of a new score using serum alkaline phosphatase and pleural effusion lactate dehydrogenase for patients with malignant pleural effusion.
Shi XY; Yi FS; Wang Z; Qiao X; Zhai K
Thorac Cancer; 2020 Feb; 11(2):320-328. PubMed ID: 31837116
[TBL] [Abstract][Full Text] [Related]
7. An Observational Study Evaluating the Performance of LENT Score in the Selected Population of Malignant Pleural Effusion from Lung Adenocarcinoma in Singapore.
Abisheganaden J; Verma A; Dagaonkar RS; Light RW
Respiration; 2018; 96(4):308-313. PubMed ID: 29945142
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Qian Q; Zhan P; Sun WK; Zhang Y; Song Y; Yu LK
Neoplasma; 2012; 59(4):433-9. PubMed ID: 22489699
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic significance of survivin levels in malignant pleural effusion.
Görgün D; Seçik F; Midilli K; Akkaya V; Yıldız P
Respir Med; 2013 Aug; 107(8):1260-5. PubMed ID: 23791464
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
[TBL] [Abstract][Full Text] [Related]
11. Important prognostic factors for survival in patients with malignant pleural effusion.
Zamboni MM; da Silva CT; Baretta R; Cunha ET; Cardoso GP
BMC Pulm Med; 2015 Mar; 15():29. PubMed ID: 25887349
[TBL] [Abstract][Full Text] [Related]
12. Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation.
Zou J; Bella AE; Chen Z; Han X; Su C; Lei Y; Luo H
J Int Med Res; 2014 Oct; 42(5):1110-7. PubMed ID: 25239875
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients.
Lee YS; Nam HS; Lim JH; Kim JS; Moon Y; Cho JH; Ryu JS; Kwak SM; Lee HL
BMC Cancer; 2017 Aug; 17(1):557. PubMed ID: 28830378
[TBL] [Abstract][Full Text] [Related]
14. Predictors of mortality within three months in the patients with malignant pleural effusion.
Ozyurtkan MO; Balci AE; Cakmak M
Eur J Intern Med; 2010 Feb; 21(1):30-4. PubMed ID: 20122610
[TBL] [Abstract][Full Text] [Related]
15. Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment.
Wang TF; Chu SC; Lee JJ; Yang GG; Huang WH; Chang ET; Low T; Wu YF; Kao RH; Lin CB
Asia Pac J Clin Oncol; 2017 Aug; 13(4):304-313. PubMed ID: 28124437
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of monitoring beta-glucuronidase in pleural effusions.
Cobben NA; Drent M; Van Dieijen-Visser MP; Mulder PG; Wouters EF; Henderson RF
Clin Biochem; 1999 Nov; 32(8):653-8. PubMed ID: 10638949
[TBL] [Abstract][Full Text] [Related]
17. Malignant pleural effusions in lymphoproliferative disorders.
Ahmed S; Shahid RK; Rimawi R; Siddiqui AK; Rossoff L; Sison CP; Steinberg H; Rai KR
Leuk Lymphoma; 2005 Jul; 46(7):1039-44. PubMed ID: 16019555
[TBL] [Abstract][Full Text] [Related]
18. Lactate dehydrogenase and creatine kinase as poor prognostic factors in lung cancer: A retrospective observational study.
Liu L; He Y; Ge G; Li L; Zhou P; Zhu Y; Tang H; Huang Y; Li W; Zhang L
PLoS One; 2017; 12(8):e0182168. PubMed ID: 28767733
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of pleural fluid data in patients with malignant effusion.
Bielsa S; Salud A; Martínez M; Esquerda A; Martín A; Rodríguez-Panadero F; Porcel JM
Eur J Intern Med; 2008 Jul; 19(5):334-9. PubMed ID: 18549935
[TBL] [Abstract][Full Text] [Related]
20. Differentiating Malignant from Tubercular Pleural Effusion by Cancer Ratio Plus (Cancer Ratio: Pleural Lymphocyte Count).
Verma A; Dagaonkar RS; Marshall D; Abisheganaden J; Light RW
Can Respir J; 2016; 2016():7348239. PubMed ID: 28070157
[No Abstract] [Full Text] [Related]
[Next] [New Search]
